<DOC>
	<DOCNO>NCT00911651</DOCNO>
	<brief_summary>The objective study assess effect salbutamol comparison ipratropium bromide geometry central peripheral airway correlate spirometric index Computational Fluid Dynamics ( CFD ) base calculate airway volume resistance compound .</brief_summary>
	<brief_title>Study Assess Effect Salbutamol Ipratropium Bromide Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description>Salbutamol ( VentolinTM ) short act beta agonist ( SABA ) use treat wheezing , dyspnea breathe difficulty cause asthma COPD . Further , also use prevent bronchospasm exercise . Ipratropium bromide ( Atrovent® HFA ) short act anticholinergic bronchodilator ( short act muscarinic antagonist ( SAMA ) ) improve lung function , dyspnea , exercise tolerance health-related quality life patient COPD . Studies also show ipratropium bromide might reduce COPD exacerbation related hospitalisation extend bronchodilatation might reduce infection rate improve clearance respiratory secretion . In open , randomize , two-way crossover , pilot study effect salbutamol patient moderate severe COPD examine comparison effect ipratropium bromide . These patient receive 400 µg salbutamol 80 µg ipratropium bromide randomize crossover design . The objective study assess effect salbutamol comparison ipratropium bromide geometry central peripheral airway correlate spirometric index ( Forced Expiratory Volume one second ( FEV1 ) Tiffeneau index ) Computational Fluid Dynamics ( CFD ) base calculate airway volume resistance compound .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . Patients document COPD base follow criterion : Smoking history least 10 packyears . Decreased Tiffeneau index ( FEV1/ ( F ) VC &lt; 0.70 ) . 2 . Patients age ≥ 40 year . 3 . Patients present moderate severe COPD FEV1 30 80 % predict ( GOLD 2 3 ) . 4 . Patients treat accord GOLD guideline . 5 . Able inhale study drug . 6 . Maintained stable respiratory medication 6 week prior visit 1 . 7 . Able perform lung function test . 8 . Able follow study procedure . 1 . Patients allergic salbutamol , ipratropium bromide another element product . 2 . Patients allergic sojalecithin product basis soja peanut . 3 . Patients ever glaucoma . 4 . Patients urinary problem , prostate hyperplasy bladderneck obstruction . Patients whose symptom control treatment may include . 5 . Patients recent history ( i.e . six month less ) myocardial infarction . 6 . Patients unstable life threaten cardiac arrhythmia . 7 . Patients severe kidney insufficiency ( creatinine clearance ≤50 ml/min ) . 8 . Patients age 40 . 9 . Patients pregnant breastfeeding . 10 . Patients treat anticholinergic medication , stop study period . 11 . A respiratory infection exacerbation COPD four week prior screen . 12 . Significant alcohol drug abuse within past 12 month . 13 . Participation another trial investigational drug within one month six half life ( whichever great ) prior screen visit . 14 . Known active tuberculosis . 15 . A history asthma , cystic fibrosis , central bronchiectasis , interstitial lung disease pulmonary thromboembolic disease . 16 . A history thoracotomy pulmonary resection . 17 . Active untreated malignancy . 18 . Use oral corticosteroid medication unstable dos ( i.e . le six week stable dose ) dose ≥ 10 mg/day . Cockroft 's formula apply : male : creatinine clearance = ( 140age ) x weight / 72 x creatininemia female : creatinine clearance = 0.85 x ( 140age ) x weight / 72 x creatininemia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>COPD</keyword>
	<keyword>salbutamol</keyword>
	<keyword>ipratropium bromide</keyword>
	<keyword>computational fluid dynamic</keyword>
	<keyword>functional imaging</keyword>
	<keyword>central peripheral airway</keyword>
</DOC>